Peptide API market report gives comprehensive outlook on peptide API across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of category (biologically active peptides, enzyme inhibitors, polypeptides, oligopeptides, and others), by therapeutic area (cancer, cardiovascular, respiratory, nervous systems, gastrointestinal, and others), by end user (biopharmaceutical companies, pharmaceutical companies, research institutes & universities, and others) and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global peptide API products. The three most common therapeutic areas where peptide APIs are used are oncology, diabetes, and obesity. Peptides are also in high demand as antibiotics and vaccines for treating cardiovascular, renal, and other diseases. Currently, injection is used to administer more than 80% of authorised peptide medicines. Oral and other forms of delivery are becoming more popular.